Inclisiran

PCSK9 inhibitors were associated with a lower risk for nonmelanoma skin cancer in older adults with atherosclerotic cardiovascular disease, in a retrospective cohort study.

Personalised 'pre-NHS' could stop onset of disease and offer health checks in places people live, work and socialise

Prescription drugs and vaccines have revolutionized healthcare, but how do researchers and industry decide what diseases to pursue?

Drug development takes a great deal of time, money and effort. While future profits play a big factor in which diseases gets prioritized, advocacy and research incentives can also tilt the scale.

Preliminary data support concept of 'molecular surgery' on PCSK9 gene

Recent developments of interest in cardiovascular medicine

Obesity or diabetes alone does not constitute a reason for screening for testosterone deficiency. But clinicians should screen for the symptoms of this deficiency.

Large meta-analysis of individual participant data shows dose-dependent type 2 diabetes increase, but vascular benefit is greater.

A team of biochemists at the Manchester Institute of Biotechnology has developed an isothermal biocatalytic process that can be used to manufacture therapeutic oligonucleotides in large volumes. In their paper published in the journal Science, the group describes their process and possible medical applications.

Bempedoic acid demonstrated effectiveness in reducing the risk of cardiac events along with statins. Study authors reported that this medication could potentially act as an alternative to more commonly prescribed cholesterol medications.

Recent developments of interest in cardiovascular medicine

Yet the good clinical data are complicated by real-world cost and access problems

Recent developments of interest in cardiovascular medicine

Recent developments of interest in cardiovascular medicine

Inclisiran, a novel small interfering RNA drug that inhibits PCSK9, made its US debut in early 2022 with cautious uptake prospects.

Highlights include new evidence on intracoronary imaging and the first inclusion of a mechanical circulatory support device in guidelines.

New indications supported by CLEAR Outcomes trial

Recent developments of interest in cardiovascular medicine

For some people, revascularization to improve symptoms or help survival also endorsed

The injectable agent's indications now include high-risk patients with primary dyslipidemia who are taking statins but who do not have a history of cardiovascular events.